OnQuality Pharmaceuticals Ltd. Company Profile

Background

OnQuality Pharmaceuticals Ltd., established in 2019, is a pharmaceutical company dedicated to developing targeted cancer supportive care therapies. The company's mission is to alleviate the adverse side effects associated with cancer treatments, thereby enhancing patients' quality of life and treatment outcomes. Operating within the oncology sector, OnQuality focuses on addressing unmet medical needs in oncodermatology and oncogastroenterology.

Key Strategic Focus

OnQuality's strategic focus centers on the development of therapies that mitigate specific side effects induced by cancer treatments. The company specializes in creating targeted supportive care agents designed to address toxicities such as skin reactions and gastrointestinal issues caused by chemotherapies, targeted cancer therapies, and immuno-oncology agents. By leveraging its proprietary, AI-enabled CARE platform, OnQuality identifies targets and drug candidates to develop first-in-disease therapies, aiming to reduce the severity and incidence of adverse events while maintaining the efficacy of cancer treatments.

Financials and Funding

On March 31, 2021, OnQuality Pharmaceuticals announced the closing of its Series A and A+ financing rounds, securing a total of $35 million. This funding was led by investors including Shiyu Capital, Matrix Partners China, BioTrack Capital, CASH Capital, Sinovation Ventures, and FreeS Fund. The capital is intended to support the ongoing Phase II clinical trial of the company's leading compound, OQL011, as well as the advancement of additional targeted cancer supportive care programs anticipated to enter various phases of clinical development over the subsequent 18 months.

Pipeline Development

OnQuality's pipeline features several key candidates:

OQL011: A topical ointment designed to treat moderate to severe Hand-Foot Skin Reaction (HFSR) associated with VEGFR inhibitors. OQL011 is currently undergoing a global multicenter, randomized, double-blinded, vehicle-controlled, dose-ranging Phase II clinical trial (NOVA-II). Part 1 of the trial met safety and efficacy expectations, and Part 2 has expanded to include sites in China and India.

OQL023: Intended for the treatment of EGFR inhibitor-induced skin rash, this candidate is undergoing IND-enabling pre-clinical studies and is expected to enter clinical trials in the near future.

OQL033: Developed for chemotherapy-induced Hand-Foot Syndrome (HFS), OQL033 is also in pre-clinical stages, with plans to commence clinical trials within the next 8-12 months.

OQL041 and OQL051: These candidates target gastrointestinal toxicities, including chemotherapy-induced diarrhea and EGFR inhibitor-induced diarrhea, and are currently in the discovery phase.

Technological Platform and Innovation

OnQuality leverages its proprietary, AI-enabled CARE platform to identify targets and drug candidates for developing first-in-disease targeted supportive therapies. This platform facilitates the discovery and development of therapies addressing unmet medical needs in oncodermatology and oncogastroenterology. By focusing on the molecular sources of treatment-related toxicities, OnQuality aims to reduce adverse events while preserving the efficacy of cancer treatments.

Leadership Team

Michael McCullar, Ph.D., MBA: Chief Executive Officer. Dr. McCullar brings over 20 years of pharmaceutical experience, including strategic planning, drug discovery, and business development. He previously served as Chief Operating Officer at Tolero Pharmaceuticals and played a significant role in its acquisition by Sumitomo Dainippon Pharma. He also held pivotal roles at Astex Pharmaceuticals and SuperGen, Inc., contributing to the FDA approval of Dacogen for myelodysplastic syndromes.

Hong Tang, M.D.: Chief Medical Officer and Co-founder. Dr. Tang is a board-certified physician with over 15 years of experience in drug development and medical affairs. She has conducted all phases of clinical trials and held positions at Dendreon, Juno, Astellas, Bristol-Myers Squibb, and the NIH.

Jie Luo: Chief Scientific Officer and Co-founder. Ms. Luo is also a principal investigator at Shanghai Jiao Tong University. She graduated from Peking University and Washington University in St. Louis and received translational and clinical research training at MIT and Harvard Medical School.

Leadership Changes

In March 2021, OnQuality appointed Dr. Michael McCullar as Chief Executive Officer. Dr. McCullar succeeded the company's founder, Shiyi Zhang, who continues to serve as a board member.

Competitor Profile

Market Insights and Dynamics

The global market for cancer therapies is projected to reach $220.5 billion by 2025, driven by the rise in cancer prevalence, advances in detection, and innovation in therapeutic development. This growth is expected to increase the demand for innovative agents in cancer supportive care, addressing the side effects of treatments to improve patient quality of life and adherence to therapy.